Clinical trial
Combination Chemotherapy With or Without PSC 833 in Treating Patients With…
NCT00002878 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00002878 |
|---|---|
| Title | Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH SWOG Cancer Research Network Cancer and Leukemia Group B NCIC Clinical Trials Group European Organisation for Research and Treatment of Cancer - EORTC |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | dexamethasone, doxorubicin hydrochloride, valspodar, vincristine sulfate |
| Start date | Jun 30, 1997 |
| Primary completion | Apr 1, 2003 |
| First posted | Jul 9, 2003 |
| Last update posted | Jun 15, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: